149705-85-1

Upstream product

• 149249-91-2 (3R,4S)-1-benzoyl-4-phenyl-3-(triethylsilyl)oxy-2-azetidinone 
• 150930-83-9 7-deshydroxy baccatine III 
• 149705-84-0 C₅₃H₆₅NO₁₃Si 
• 873779-19-2 C₅₅H₆₇NO₁₄S₂Si 
• 33069-62-4 taxol 
• 114655-02-6 2'-O-(tert-butyldimethylsilyl)paclitaxel 
• 146257-44-5 9-O-Acetyl-5-O-cinnamoyltaxicine I 
• 214192-72-0 C₂₃H₂₈O₉ 
• 214192-67-3 C₂₃H₃₀O₁₀ 
• 214192-73-1 C₂₅H₃₀O₁₀ 
• 214192-68-4 C₂₉H₄₄O₁₀Si 
• 214192-65-1 C₃₂H₃₄O₉ 
• 214192-64-0 10-O-Acetyl-5-O-cinnamoyltaxicine 1,2-carbonate 
• 214192-70-8 C₂₄H₃₂O₁₂S 

Downstream Products

• 148121-24-8 10-deacetoxy-paclitaxel 
• 204981-02-2 C₅₈H₇₇NO₁₃Si₂ 
• 204981-04-4 C₅₄H₆₇NO₁₃SSi 
• 204981-05-5 C₅₄H₆₇NO₁₄Si 
• 204981-03-3 C₅₂H₆₃NO₁₃Si 
• 162664-54-2 2'-O-TBDMS-7-O-TES-9,10-diketo-paclitaxel 

Relevant academic research and scientific papers

Synthesis and interactions of 7-deoxy-, 10-deacetoxy, and 10-deacetoxy-7-deoxypaclitaxel with NCI/ADR-RES cancer cells and bovine brain microvessel endothelial cells

7-Deoxypaclitaxel, 10-deacetoxypaclitaxel and 10-deacetoxy-7- deoxypaclitaxel were prepared and evaluated for their ability to promote assembly of tubulin into microtubules, their cytotoxicity against NCI/ADR-RES cells and for their interactions with P-gl

An efficient semisynthesis of 7-deoxypaclitaxel from taxine

A semisynthesis of 7-deoxypaclitaxel 4 is described, starting from taxine 6 - the most abundant naturally occurring taxane diterpene fraction. A key step in this transformation is a tandem reaction: stereoselective osmylation of cinnamic ester 14/intramolecularly assisted methanolysis of 16, which gives the key intermediate 5, along with the optically pure ester 17 - a precursor for the synthesis of the paclitaxel side-chain. In this way, the cinnamoyltaxicine 9 is converted into 7-deoxybaccatin III 25 in 11 steps, and in 15% overall yield.

An efficient semisynthesis of 7-deoxypaclitaxel from taxine

Highly cytotoxic 7-deoxypaclitaxel analogues are obtained by a semisynthesis starting from taxine - the most abundant naturally occurring taxane diterpene fraction.

Deoxy taxols

Rg is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, or a radical of the formula --W--Rx in which W is a bond, C2-6 alkenediyl, or --(CH2)t --, in which t is one to six; and Rx is naphthyl, phenyl, or heteroaryl, and furthermore Rx can be optionally substituted with one to three same or different C1-6 alkyl, C1-6 alkoxy, halogen or --CF3 groups; R2 is --OCOR, H, OH, --OR, --OSO2 R, --OCONRo R, --OCONHR, --OCOO(CH2)t R, or --OCOOR; and R and Ro are independently C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, C2-6 alkynyl, or phenyl, optionally substituted with one to three same or different C1-6 alkyl, C1-6 alkoxy, halogen or --CF3 groups. Further provided by this invention are pharmaceutical formulations and intermediates for the the preparation of deoxy taxols of formula I. A method of treating mammalian tumors using a compound of formula I is also provided.

Synthesis of 7-Deoxy- and 7,10-Dideoxytaxol via Radical Intermediates

7-Deoxytaxol and 7,10-dideoxytaxol were prepared from baccatin III, employing the Barton deoxygenation procedure and the Holton acylation method at C-13.

Phosphonooxy and carbonate derivatives of taxol

The present invention is directed to novel taxol derivatives useful as anti-tumor agents. Also provided by this invention is pharmaceutical formulations and methods of treating mammalian tumors with the compounds of this invention.